BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

872 related articles for article (PubMed ID: 17602732)

  • 1. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.
    Paavonen J; Jenkins D; Bosch FX; Naud P; Salmerón J; Wheeler CM; Chow SN; Apter DL; Kitchener HC; Castellsague X; de Carvalho NS; Skinner SR; Harper DM; Hedrick JA; Jaisamrarn U; Limson GA; Dionne M; Quint W; Spiessens B; Peeters P; Struyf F; Wieting SL; Lehtinen MO; Dubin G;
    Lancet; 2007 Jun; 369(9580):2161-2170. PubMed ID: 17602732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.
    Paavonen J; Naud P; Salmerón J; Wheeler CM; Chow SN; Apter D; Kitchener H; Castellsague X; Teixeira JC; Skinner SR; Hedrick J; Jaisamrarn U; Limson G; Garland S; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Jenkins D; Hardt K; Zahaf T; Descamps D; Struyf F; Lehtinen M; Dubin G;
    Lancet; 2009 Jul; 374(9686):301-14. PubMed ID: 19586656
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
    Wheeler CM; Castellsagué X; Garland SM; Szarewski A; Paavonen J; Naud P; Salmerón J; Chow SN; Apter D; Kitchener H; Teixeira JC; Skinner SR; Jaisamrarn U; Limson G; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; Bosch FX; Harper DM; Huh W; Hardt K; Zahaf T; Descamps D; Struyf F; Dubin G; Lehtinen M;
    Lancet Oncol; 2012 Jan; 13(1):100-10. PubMed ID: 22075170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors.
    Arbyn M; Xu L; Simoens C; Martin-Hirsch PP
    Cochrane Database Syst Rev; 2018 May; 5(5):CD009069. PubMed ID: 29740819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
    Skinner SR; Szarewski A; Romanowski B; Garland SM; Lazcano-Ponce E; Salmerón J; Del Rosario-Raymundo MR; Verheijen RH; Quek SC; da Silva DP; Kitchener H; Fong KL; Bouchard C; Money DM; Ilancheran A; Cruickshank ME; Levin MJ; Chatterjee A; Stapleton JT; Martens M; Quint W; David MP; Meric D; Hardt K; Descamps D; Geeraerts B; Struyf F; Dubin G;
    Lancet; 2014 Dec; 384(9961):2213-27. PubMed ID: 25189358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials.
    Ault KA;
    Lancet; 2007 Jun; 369(9576):1861-1868. PubMed ID: 17544766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precancerous cervical lesions caused by non-vaccine-preventable HPV types after vaccination with the bivalent AS04-adjuvanted HPV vaccine: an analysis of the long-term follow-up study from the randomised Costa Rica HPV Vaccine Trial.
    Shing JZ; Hu S; Herrero R; Hildesheim A; Porras C; Sampson JN; Schussler J; Schiller JT; Lowy DR; Sierra MS; Carvajal L; Kreimer AR;
    Lancet Oncol; 2022 Jul; 23(7):940-949. PubMed ID: 35709811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of the bivalent HPV vaccine against HPV 16/18-associated precancer: long-term follow-up results from the Costa Rica Vaccine Trial.
    Porras C; Tsang SH; Herrero R; Guillén D; Darragh TM; Stoler MH; Hildesheim A; Wagner S; Boland J; Lowy DR; Schiller JT; Schiffman M; Schussler J; Gail MH; Quint W; Ocampo R; Morales J; Rodríguez AC; Hu S; Sampson JN; Kreimer AR;
    Lancet Oncol; 2020 Dec; 21(12):1643-1652. PubMed ID: 33271093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
    Lehtinen M; Paavonen J; Wheeler CM; Jaisamrarn U; Garland SM; Castellsagué X; Skinner SR; Apter D; Naud P; Salmerón J; Chow SN; Kitchener H; Teixeira JC; Hedrick J; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; De Carvalho NS; Germar MJ; Peters K; Mindel A; De Sutter P; Bosch FX; David MP; Descamps D; Struyf F; Dubin G;
    Lancet Oncol; 2012 Jan; 13(1):89-99. PubMed ID: 22075171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials.
    Tota JE; Struyf F; Sampson JN; Gonzalez P; Ryser M; Herrero R; Schussler J; Karkada N; Rodriguez AC; Folschweiller N; Porras C; Schiffman M; Schiller JT; Quint W; Kreimer AR; Wheeler CM; Hildesheim A;
    J Natl Cancer Inst; 2020 Aug; 112(8):818-828. PubMed ID: 31697384
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial.
    Zhu FC; Chen W; Hu YM; Hong Y; Li J; Zhang X; Zhang YJ; Pan QJ; Zhao FH; Yu JX; Zhang YS; Yang X; Zhang CF; Tang H; Zhang H; Lebacq M; David MP; Datta SK; Struyf F; Bi D; Descamps D;
    Int J Cancer; 2014 Dec; 135(11):2612-22. PubMed ID: 24740596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
    Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
    BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study.
    Wheeler CM; Skinner SR; Del Rosario-Raymundo MR; Garland SM; Chatterjee A; Lazcano-Ponce E; Salmerón J; McNeil S; Stapleton JT; Bouchard C; Martens MG; Money DM; Quek SC; Romanowski B; Vallejos CS; Ter Harmsel B; Prilepskaya V; Fong KL; Kitchener H; Minkina G; Lim YKT; Stoney T; Chakhtoura N; Cruickshank ME; Savicheva A; da Silva DP; Ferguson M; Molijn AC; Quint WGV; Hardt K; Descamps D; Suryakiran PV; Karkada N; Geeraerts B; Dubin G; Struyf F;
    Lancet Infect Dis; 2016 Oct; 16(10):1154-1168. PubMed ID: 27373900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection.
    Haupt RM; Wheeler CM; Brown DR; Garland SM; Ferris DG; Paavonen JA; Lehtinen MO; Steben M; Joura EA; Giacoletti KE; Radley DR; James MK; Saah AJ; Sings HL;
    Int J Cancer; 2011 Dec; 129(11):2632-42. PubMed ID: 21491420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials.
    Joura EA; Leodolter S; Hernandez-Avila M; Wheeler CM; Perez G; Koutsky LA; Garland SM; Harper DM; Tang GW; Ferris DG; Steben M; Jones RW; Bryan J; Taddeo FJ; Bautista OM; Esser MT; Sings HL; Nelson M; Boslego JW; Sattler C; Barr E; Paavonen J
    Lancet; 2007 May; 369(9574):1693-702. PubMed ID: 17512854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of human papillomavirus 16/18 AS04-adjuvanted vaccine in Japanese women aged 20 to 25 years: interim analysis of a phase 2 double-blind, randomized, controlled trial.
    Konno R; Tamura S; Dobbelaere K; Yoshikawa H
    Int J Gynecol Cancer; 2010 Apr; 20(3):404-10. PubMed ID: 20375805
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical intraepithelial neoplasia and cervical infection in young Japanese women.
    Konno R; Yoshikawa H; Okutani M; Quint W; V Suryakiran P; Lin L; Struyf F
    Hum Vaccin Immunother; 2014; 10(7):1781-94. PubMed ID: 25424783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of the HPV-16/18 vaccine: final according to protocol results from the blinded phase of the randomized Costa Rica HPV-16/18 vaccine trial.
    Hildesheim A; Wacholder S; Catteau G; Struyf F; Dubin G; Herrero R;
    Vaccine; 2014 Sep; 32(39):5087-97. PubMed ID: 25018097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial.
    Garland SM; Paavonen J; Jaisamrarn U; Naud P; Salmerón J; Chow SN; Apter D; Castellsagué X; Teixeira JC; Skinner SR; Hedrick J; Limson G; Schwarz TF; Poppe WA; Bosch FX; de Carvalho NS; Germar MJ; Peters K; Del Rosario-Raymundo MR; Catteau G; Descamps D; Struyf F; Lehtinen M; Dubin G;
    Int J Cancer; 2016 Dec; 139(12):2812-2826. PubMed ID: 27541373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.
    Harper DM; Franco EL; Wheeler CM; Moscicki AB; Romanowski B; Roteli-Martins CM; Jenkins D; Schuind A; Costa Clemens SA; Dubin G;
    Lancet; 2006 Apr; 367(9518):1247-55. PubMed ID: 16631880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.